“This is an important treatment option and today is a proud day for CSL Seqirus as an Australian company,” said CSL Seqirus Executive Medical Director Dr Jonathan Anderson. “We look forward to seeing decision-makers assess our application for funding so that more Australians can access NEFFY.” …
'It’s the first time in over 30 years that a new way of administering adrenaline has been approved in Australia'
February 16, 2026 Latest NewsBioPharma
Latest Video
New Stories
-
Australian company secures European approval for rare disease treatment
August 26, 2026 - - Latest News -
Australia cannot deliver meaningful change until the levers of power are rebalanced
August 26, 2026 - - Latest News -
Insurers warn cut could hit Australians most likely to need cancer care
August 25, 2026 - - Latest News -
Australian study finds maternal RSV vaccination offers strong protection for infants
August 25, 2026 - - Latest News -
Acrux brings experienced clinical leader aboard to advance testosterone program
August 24, 2026 - - Australian Biotech -
Avecho moves to deepen global partnering push as CBD insomnia program advances
August 24, 2026 - - Australian Biotech -
July recommendations across oncology, rare disease and chronic care
August 24, 2026 - - Latest News